98%
921
2 minutes
20
Background And Objectives: The aim of this study is to develop a radiomic and deep learning-based signature for survival analysis of patients with Non-Small Cell Lung Cancer.
Methods: Four-hundred twenty-two patients from "Lung1" dataset were included in the study. A 3D convolutional autoencoder (AE) was built and features from the latent space extracted for further analysis. Radiomic features were derived from the 3D volume of the tumor region using PyRadiomics. Both radiomic and AE-based features underwent feature selection, by removing: i) highly correlated and ii) constant features. The selected variables were then used to derive both mono-domain (radiomics, AE and clinic) and multi-domain signatures fitting a Cox Proportional Hazard model with LASSO penalization and evaluated considering the concordance (C)-index as performance metric.
Results: Both mono-domain and multi-domain signatures could significantly differentiate high risk from low risk patients. Among the mono-domain signatures, the highest hazard ratio (HR) in the test set was obtained using radiomics (HR = 1.5428) followed by the AE-based signature (HR = 1.5012) and the clinical signature (HR = 1.4770). The best overall performance was achieved by combining all three signatures, resulting in the highest HR (HR = 1.7383), while the combination of AE-based and clinical signatures yielded the highest C-index (C-index = 0.6309).
Conclusions: These preliminary results show that combining information carried by AE, radiomic and clinical domain shows potential for improving the prediction of overall survival in NSCLC patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cmpb.2024.108496 | DOI Listing |
JAMA Netw Open
September 2025
Oncostat U1018, Institut National de la Santé et de la Recherche Médicale (INSERM), Ligue Contre le Cancer, Paris-Saclay University, Villejuif, France.
Importance: Antibiotics, steroids, and proton pump inhibitors (PPIs) are suspected to decrease the efficacy of immunotherapy.
Objective: To explore the association of comedications with overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC).
Design, Setting, And Participants: This nationwide retrospective cohort study used target trial emulations of patients newly diagnosed with NSCLC from January 2015 to December 2022, identified from the French national health care database.
J Pharm Pharmacol
September 2025
Department of Clinical Pharmacy, Hebei Medical University Third Hospital. No. 139 Ziqiang Road, Qiaoxi District, Shijiazhuang 050051, China.
Objectives: To investigate the antitumor effects of aucubin (AC) in non-small cell lung cancer (NSCLC) and uncover its plausible mechanism against lung cancer stem-like cells (LCSCs).
Methods: In vitro experiments included MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a reagent commonly used for cell viability assay) and colony formation assays to assess anti-proliferative effects on A549 and NCI-H1975 lung cancer cell lines, wound healing and Transwell invasion assays to evaluate inhibition of cell migration and invasion, tumorsphere-formation experiments to detect changes in NSCLC cell stemness, as well as Western blot and quantitative reverse transcription polymerase chain reaction (qRT-PCR) analyses to measure the expression of LCSC markers (CD44, CD133, Oct4, and Nanog). In vivo experiments were conducted to observe the impact of AC on NSCLC metastasis and mouse survival rates.
Int J Surg
September 2025
Department of Thoracic Surgery, Changchun Tumor Hospital.
Objective: The risk factors of postoperative survival in T4N0M0 NSCLC patients are not fully understood. This study aimed to develop and validate a nomogram model for predicting postoperative survival in patients with T4N0M0 non-small cell lung cancer (NSCLC).
Methods: Clinicopathological data of patients were collected from Surveillance, Epidemiology, and End Results (SEER) database.
Front Immunol
September 2025
Department of Thoracic Surgery, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University), Shenzhen, Guangdong, China.
Background: Lung cancer remains the leading cause of cancer-related mortality globally, primarily due to late-stage diagnosis, molecular heterogeneity, and therapy resistance. Key biomarkers such as EGFR, ALK, KRAS, and PD-1 have revolutionized precision oncology; however, comprehensive structural and clinical validation of these targets is crucial to enhance therapeutic efficacy.
Methods: Protein sequences for EGFR, ALK, KRAS, and PD-1 were retrieved from UniProt and modeled using SWISS-MODEL to generate high-confidence 3D structures.
J Immunother Precis Oncol
August 2025
Department of Medical Oncology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, India.
Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of non-small cell lung cancer (NSCLC) with limited treatment options and poor prognosis. mutations generally respond to tyrosine kinase inhibitors (TKIs)-based targeted therapy but are typically associated with resistance to immunotherapy. We report a case of oligometastatic PSC harboring compound mutations (p.
View Article and Find Full Text PDF